Introduction
============

According to the Global Cancer Statistics 2018, bladder cancer is the tenth most common form of cancer and the ninth leading cause of cancer-associated mortality worldwide ([@b1-ol-0-0-11227]). At initial diagnosis, \~70% of patients with bladder cancer exhibit non-muscle invasive bladder cancer; however, over a 5-year period the risk of recurrence has been identified to vary between 30 and 80%, and \~15% of cases of bladder cancer progress to muscle invasion ([@b2-ol-0-0-11227]). Therefore, early diagnosis and long-term surveillance of patients with bladder cancer are crucial. The current diagnostic and postoperative surveillance strategies are based on the combination of cystoscopy and voided urine cytology ([@b3-ol-0-0-11227]). Although these two methods are regarded as the gold standard for the diagnosis of bladder cancer, they have certain disadvantages. Cystoscopy, which is an invasive procedure, results in high costs for the healthcare system and the discomfort of patients ([@b4-ol-0-0-11227]). Additionally, the symptoms and their duration after cystoscopy induced pain during urination (50%), increased urinary frequency (37%), visible hematuria (19%) and infection (3%) ([@b5-ol-0-0-11227],[@b6-ol-0-0-11227]). Furthermore, this procedure has been demonstrated to exhibit low sensitivity in the detection of carcinoma *in situ*, and tumors may be missed due to its operator-dependent effectiveness ([@b7-ol-0-0-11227]). Overall sensitivity of urine cytology has been identified to range between 28 and 100%, with a median of 44%; however, this procedure exhibits high sensitivity for detecting high-grade tumors and low sensitivity for low-grade tumors (range, 4--31%) ([@b8-ol-0-0-11227]). In addition, negative cytology does not exclude the presence of a tumor as cytological results are patient-dependent and may be hindered by several factors, including low cellular yield, urinary tract infections and stones ([@b9-ol-0-0-11227]).

Great efforts have been made to develop new tests with high diagnostic efficiency and reproducibility and low cost for the non-invasive detection of bladder cancer. To date, numerous potential urinary biomarkers have been suggested and the use of molecular biomarkers for bladder cancer surveillance has demonstrated potential clinical applicability ([@b4-ol-0-0-11227],[@b10-ol-0-0-11227]). Examples of these biomarkers include nuclear matrix protein 22, survivin, matrix metallopeptidase 9, bladder tumor antigen, cytokeratin, urinary bladder carcinoma antigen and Cyfra 21-1 ([@b11-ol-0-0-11227]).

Survivin is the smallest inhibitor of apoptosis protein with a single amino-terminal BIR domain and carboxy-terminal Coiled Coil domain ([@b12-ol-0-0-11227]). Survivin is a critical regulator of mitosis, and an inhibitor of apoptosis, which promotes the proliferation of tumor cells, induces angiogenesis and thus increases the invasion capacity of tumors ([@b13-ol-0-0-11227]). The expression of survivin is undetectable in terminally differentiated and mature tissues but is highly expressed in common types of human cancer, including lung, colon, pancreas, prostate and breast ([@b14-ol-0-0-11227]) cancer. Therefore, it is considered to be a new tumor marker, which may be useful in the diagnosis of human cancer ([@b12-ol-0-0-11227]). Swana *et al* ([@b15-ol-0-0-11227]) reported that survivin was expressed in 78% of patients with bladder cancer, as detected by immunohistochemistry (IHC), but was absent in normal bladder urothelium. Smith *et al* ([@b16-ol-0-0-11227]) detected the expression of survivin protein and mRNA in urine samples from patients with bladder cancer by Bio-Dot immunoassay and reverse transcription-PCR (RT-PCR), respectively, in 2001. In the following years, certain studies assessed the detection of survivin protein in urine samples using IHC, ELISA or Bio-Dot immunoassay as a means of diagnosing bladder cancer. The detection of urinary survivin expression has been identified by Bio-Dot immunoassay to be an accurate diagnostic method for bladder cancer that retains its efficiency regardless of tumor stage and grade ([@b17-ol-0-0-11227]). In addition to the survivin protein, the survivin gene has gradually gained interest as a marker for the diagnosis and treatment of bladder cancer. An increasing number of studies have examined the expression of survivin mRNA in urine by RT-PCR for the diagnosis of bladder cancer. A meta-analysis by Liang *et al* ([@b18-ol-0-0-11227]) concluded that both survivin protein and mRNA may be used as biomarkers for bladder cancer detection, and survivin RNA exhibited higher accuracy compared with survivin protein. In addition, numerous studies have demonstrated the various accuracy of RT-PCR detection of urinary survivin mRNA expression in the diagnosis of bladder cancer. Weikert *et al* ([@b19-ol-0-0-11227]) reported a sensitivity of 68.6% and a specificity of 100% was identified in 53 patients with bladder cancer. Pu *et al* ([@b20-ol-0-0-11227]) reported a sensitivity of 90.4% and a specificity of 96.6% for the diagnosis of bladder cancer. Eissa *et al* ([@b21-ol-0-0-11227]) reported a sensitivity of 76.1% and a specificity of 95.0% in 86 patients.

The aim of the present meta-analysis was to review and summarize the results of previous experimental studies confirming the potential diagnostic value of urinary survivin mRNA as a marker for bladder cancer, and to compare this test by RT-PCR with traditional cytology. In addition, the present study aimed to assess the quality of published studies.

Materials and methods
=====================

### Search strategy

The present meta-analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@b22-ol-0-0-11227]). Scientific databases, including PubMed, Web of Science, Cochrane Library and China National Knowledge Infrastructure (CNKI), were comprehensively searched for publications between January 2001 and January 2019 to identify studies on the use of urinary survivin mRNA expression and urine cytology in the diagnosis of bladder cancer. The published literature search was conducted in English and restricted to original research studies. Published studies in the CNKI database were searched using Chinese-language characters, since this database contains research papers published in Chinese. The following terms, which are Medical Subject Headings key words, were searched in the text, title or abstract of relevant studies: 'Bladder cancer' or 'carcinoma of bladder' or 'urothelial carcinoma of the urinary tract' and 'survivin'. Similar publications identified in the reference lists of the retrieved studies were also obtained.

### Selection criteria

The retrieved studies were independently reviewed by two reviewers, who agreed on which studies were eligible for the present meta-analysis; discrepancies were discussed and resolved by consensus. The following inclusion criteria were applied to the published studies retrieved by the database search: i) Studies published in English or Chinese; ii) studies that included a 2×2 contingency table; iii) urinary survivin mRNA expression detected by RT-PCR; iv) urine cytology as a comparison test and v) cystoscopy and/or histopathology used as the gold standard. Furthermore, the following exclusion criteria were applied: i) Case reports, case series and review studies; ii) animal or cell experiments; iii) use of immunohistochemical staining or western blot detection of survivin; iv) patients with urinary tract tumors other than bladder cancer or v) incomplete clinical data.

### Data extraction and quality assessment

The following primary outcome data were extracted from the studies included in the meta-analysis: i) True positives (TP); ii) false positives (FP); iii) false negatives (FN); iv) true negatives (TN); and v) the total number of patients enrolled in each study. Additional data included: i) The name of the first author; ii) publication year; iii) country; iv) study design and v) gold standard. The Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool ([@b23-ol-0-0-11227]) was used to rate the quality of each of the included studies. This method consisted of four components, the selection of cases, trials to be assessed, gold standards and the flowcharts and progress of cases. Each of the assessments comprised seven items and the corresponding responses contained the terms 'yes', 'no' or 'uncertainty'. Positive answers ('yes') meant that the risk bias of a study was considered low, whereas negative ('no') and uncertain ('uncertainty') answers meant that the risk of bias was high.

### Statistical analysis

Data analysis was performed using the midas ([@b24-ol-0-0-11227]--[@b27-ol-0-0-11227]) and metan \[version 1.85; ([@b28-ol-0-0-11227])\] packages in Stata/MP (version 15.0; StataCorp, LLC). Revman 5.3 (version 5.3; The Nordic Cochrane Centre, The Cochrane Collaboration) was used for quality assessment. The sensitivity (Sen), specificity (Spe), positive likelihood ratios (PLRs), negative likelihood ratios (NLRs) and corresponding 95% confidence intervals (CIs) were calculated using the TP, FP, FN and TN values, which were extracted from each study prior to data pooling. The summary receiver operating characteristic curve (SROC) was constructed based on a bivariate regression approach and the pooled estimate for sensitivity and specificity was subsequently calculated. The diagnostic odds ratio (DOR) with 95% CI and Youden\'s index (γ=Sensitivity + Specificity-1) were also calculated. In addition, Fagan nomograms were generated to evaluate the clinical utility of the two diagnostic methods. Heterogeneity among the reports was assessed by the χ^2^ test (Cochran Q test) and the I^2^ statistic. The DerSimonian Laird method for pooled analyses was used for I^2^ values \>50%. Statistical heterogeneity was considered to be low when I^2^ was 25--49%, moderate when I^2^ was 50--74% and high when I^2^ was \>75 ([@b29-ol-0-0-11227]). In addition, Deeks\' funnel plot asymmetry test based on parametric linear regression was used to identify the possibility of publication bias ([@b25-ol-0-0-11227]). As the primary aim of the present study was to assess the accuracy of urinary survivin mRNA expression in the early diagnosis of bladder cancer, Deeks\' funnel plot was generated only for urinary survivin mRNA.

To compare urinary survivin mRNA expression with urine cytology, data of the pathological grade, stage and pooled sensitivity were collected. In addition, a paired χ^2^ test was performed for prime diagnostic indicators, sensitivity and specificity. A Z test was used to analyze the area under the curve (AUC) and Youden\'s index. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Search results and selected studies

The results of the current meta-analysis selection process are presented in [Fig. 1](#f1-ol-0-0-11227){ref-type="fig"}. The initial search resulted in 959 studies, 490 of which were duplicates and were thus excluded. A total of two reviewers read the titles and abstracts of the remaining 469 studies; 428 irrelevant studies were removed by consensus. A total of 41 potentially eligible studies were selected; following reading the full text of each study and analyzing the results, 26 studies were excluded due to a lack of complete data or incomplete descriptions of the trials. A total of 15 eligible studies were included in the meta-analysis.

### Included study characteristics

The main characteristics of the included studies are presented in [Table I](#tI-ol-0-0-11227){ref-type="table"}. The studies were from Germany ([@b19-ol-0-0-11227]), Kuwait ([@b30-ol-0-0-11227]), Portugal ([@b31-ol-0-0-11227]), Egypt ([@b21-ol-0-0-11227],[@b32-ol-0-0-11227],[@b33-ol-0-0-11227]) and China ([@b20-ol-0-0-11227],[@b34-ol-0-0-11227]--[@b41-ol-0-0-11227]), and eight of them were published in English. A total of 1,624 patients were included in the studies, 951 of which were diagnosed with bladder cancer. The remaining 673 control participants comprised healthy participants and patients with benign prostate hyperplasia, urinary tract infection, urethral stricture or urolithiasis and benign epithelial neoplasm of the bladder.

### Quality assessment of the included studies

The quality assessment results of the included studies are presented in [Fig. 2](#f2-ol-0-0-11227){ref-type="fig"}. Regarding patient selection, certain studies were identified to exhibit a high risk of bias since healthy patients were used as the control group, whereas others used non-malignant diseases of the urinary system as controls. The index test in the QUADAS-2 tool was associated with a high risk of bias, as study thresholds, reagents and procedure were often different. Regarding the reference standard, low risk of bias was identified. The flow and timing characteristic were associated with a low risk of bias.

### Pooled data for all included studies

[Table II](#tII-ol-0-0-11227){ref-type="table"} presents the pairwise comparisons of prime diagnostic indicators between urinary survivin mRNA expression and urine cytology. The pooled Sen for urinary survivin mRNA expression and urine cytology were 0.86 (95% CI, 0.81--0.90; [Fig. 3](#f3-ol-0-0-11227){ref-type="fig"}) and 0.42 (95% CI, 0.36--0.48; [Fig. 4](#f4-ol-0-0-11227){ref-type="fig"}), respectively; the pooled Spe for urinary survivin mRNA expression and urine cytology were 0.95 (95% CI, 0.93--0.96; [Fig. 3](#f3-ol-0-0-11227){ref-type="fig"}) and 1.00 (95% CI, 0.98--1.00; [Fig. 4](#f4-ol-0-0-11227){ref-type="fig"}), respectively. The areas under the curve (AUC) for urinary survivin mRNA expression and urine cytology were 0.95 (95% CI, 0.93--0.97; [Fig. 5A](#f5-ol-0-0-11227){ref-type="fig"}) and 0.86 (95% CI, 0.83--0.89; [Fig. 5B](#f5-ol-0-0-11227){ref-type="fig"}). The summary estimates of DOR for urinary survivin mRNA expression and urine cytology were 83.42 (95% CI, 49.70--139.96) and 42.00 (95% CI, 22.95--76.89), respectively; the pooled PLRs for urinary survivin mRNA expression and urine cytology were 16.4 (95% CI, 11.6--23.2) and 178.5 (95% CI, 25.1--1269.7) and the pooled NLRs were 0.14 (95% CI, 0.10--0.20) and 0.59 (95% CI, 0.53--0.65), respectively ([Table II](#tII-ol-0-0-11227){ref-type="table"}).

Fagan plot analysis was used to evaluate the differences in clinical utility between urinary survivin mRNA expression and urine cytology for the diagnosis of bladder cancer. Regarding the detection of urinary survivin mRNA expression, the probability of bladder cancer increased from 20 to 80% when the test was positive and decreased to 3% when the results were negative ([Fig. 6A](#f6-ol-0-0-11227){ref-type="fig"}). For urine cytology, the probability of bladder cancer increased from 20 to 98% when the results were positive and decreased to 13% when the results were negative. The potential publication bias was evaluated by Deeks\' funnel plot ([Fig. 7](#f7-ol-0-0-11227){ref-type="fig"}).

Discussion
==========

Bladder cancer is a complex type of cancer with variable biological and clinical characteristics that has the tendency to recur and progress ([@b42-ol-0-0-11227]). Cystoscopy is 'gold standard' diagnostic procedure for bladder cancer, which can be invasive, expensive, and increase risk for urologic disease in patients ([@b43-ol-0-0-11227],[@b44-ol-0-0-11227]). Although urine cytology has high specificity (range, 85--100%), it is associated with low overall sensitivity (range, 11--76%) depending on tumor grade and is not suitable for preliminary screening in the diagnosis of bladder cancer ([@b10-ol-0-0-11227]). Survivin, which is a potential biomarker for urinary cancer, appears promising and worth validating in a prospective study with regards to its diagnostic and prognostic ability and clinical relevance ([@b4-ol-0-0-11227],[@b10-ol-0-0-11227],[@b45-ol-0-0-11227]). Shariat *et al* ([@b17-ol-0-0-11227]) have demonstrated that urinary survivin protein may be a predictor of high-grade bladder tumors and Weikert *et al* ([@b19-ol-0-0-11227]) have detected survivin mRNA expression in urine samples from 68.6% of patients with bladder cancer. Currently, there are several methods available to detect survivin expression, including IHC, ELISA and RT-PCR ([@b46-ol-0-0-11227]). Although IHC is regarded as a gold standard for the diagnosis of cancer, its use is restricted by the fact that tissue specimens are not easily obtained. Since survivin is a non-secreted short-lived protein, certain methods to detect its expression are based on the abundance of malignant cells in the urine sediment ([@b47-ol-0-0-11227],[@b48-ol-0-0-11227]). Although ELISA is considered a highly accurate method, it is limited to a certain extent due to being time-consuming and exhibiting poor uniformity ([@b46-ol-0-0-11227]). In addition, protein-based assays are limited by insufficient antibody specificity and detection sensitivity lower compared with that of RT-PCR assays ([@b49-ol-0-0-11227]). RT-PCR exhibits very high sensitivity and is a well-established method able to exponentially amplify and quantify minuscule amounts of nucleic acids in malignant cells in the urinary sediment. Compared with RT-PCR, ELISA exhibits lower sensitivity (0.75; 95% CI, 0.71--0.79) ([@b18-ol-0-0-11227]). The present study demonstrated that RT-PCR based assays may have high sensitivity, especially for the detection of the early stages of bladder cancer.

The aim of the present study was to perform a meta-analysis of published literature investigating urinary survivin mRNA expression detection by RT-PCR compared with urine cytology in the diagnosis of bladder cancer. The results demonstrated good diagnostic accuracy of urinary survivin mRNA expression and urine cytology for bladder cancer, but they showed their own different characteristics. The pooled sensitivity of urinary survivin mRNA expression was higher compared with that of urine cytology, and the difference was statistically significant in the diagnosis of grade 1 and 2 bladder tumors. These findings revealed that the expression of survivin may be associated with the degree of malignancy of bladder cancer, although its role in tumor metastasis and progression remains unclear. Regarding pooled specificity, urine cytology was higher compared with urinary survivin mRNA expression; as for SROC, urinary survivin mRNA expression was higher, but neither of these parameters were observed to exhibit statistically significant differences. Pooled PLRs \>10 and pooled NLRs \<0.1 were considered to provide convincing diagnostic evidence. PLRs \>5 provide strong diagnostic evidence to rule in diagnoses; NLRs \<0.2 provide strong diagnostic evidence to rule out diagnoses, in the majority of cases ([@b50-ol-0-0-11227]). In the present study, the NLR was 0.59 for urine cytology, which suggested that if the outcome for this method was negative, 59% of the patients may still have bladder cancer. However, the NLR for urinary survivin mRNA expression was 0.14, indicating that 14% of patients may be misdiagnosed. Based on the assessed parameters from the retrieved studies, including Sen, Spe, AUC, PLR, NLR and DOR, the results of the present study demonstrated that survivin mRNA exhibited potential as a biomarker for the diagnosis of bladder cancer.

The present meta-analysis has several limitations. First, the results demonstrated that the heterogeneity between studies should not be ignored. Despite performing the subgroup and sensitivity analysis, heterogeneity was still detected. The DerSimonian Laird method was used for pooled analyses. The heterogeneity of the pooled studies was low to moderate in all analyses. This limitation is difficult to discuss since the individual studies in this meta-analysis contained different control groups. In previous studies, non-malignant diseases of the urinary system were assigned as the control groups ([@b37-ol-0-0-11227],[@b38-ol-0-0-11227]). In two of the studies, healthy participants were assigned to the control groups ([@b30-ol-0-0-11227],[@b31-ol-0-0-11227]). In other studies, healthy participants and non-malignant diseases of the urinary system were assigned as the control groups ([@b19-ol-0-0-11227]--[@b21-ol-0-0-11227], [@b32-ol-0-0-11227]--[@b36-ol-0-0-11227], [@b39-ol-0-0-11227]--[@b41-ol-0-0-11227]). Certain studies focused on diagnostics ([@b16-ol-0-0-11227],[@b21-ol-0-0-11227],[@b30-ol-0-0-11227],[@b32-ol-0-0-11227],[@b33-ol-0-0-11227]), whereas others focused on the use of urinary mRNA expression as a tumor marker; however, there is not sufficient data to predict the recurrence of bladder cancer ([@b19-ol-0-0-11227],[@b31-ol-0-0-11227]). The pooled sensitivity and specificity for urinary survivin mRNA expression were 0.86 and 0.94, respectively, indicating that the urinary survivin mRNA expression analysis via RT-PCR was accurate. Only studies written in English and Chinese were included; studies published in other languages were excluded, which may have led to further bias in this study. The experimental equipment and reagents of each laboratory and the threshold setting of urinary survivin mRNA expression may also vary.

Compared with traditional urine cytology, RT-PCR has the following advantages: i) Easy collection of urine samples; ii) high diagnostic accuracy; iii) low rate of missed diagnoses; and iv) simple procedure without discomfort for the patient. Furthermore, an important advantage of detecting urinary survivin mRNA expression using RT-PCR is its high sensitivity.

In summary, urinary survivin mRNA expression may serve as a screening marker for the diagnosis of bladder cancer. However, prior to its application in the clinical setting, a large prospective study is required in order to verify the accuracy of the RT-PCR assay and identify the optimal cut-off value clinical.
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![Assessment of the risk of bias of the included studies using the Quality Assessment of Diagnostic Accuracy Studies 2 tool. Presented is the proportion of studies with low (white), unclear (gray) and high (black) risk of bias. Each bar indicates the number and percentage of studies.](ol-19-02-1165-g01){#f2-ol-0-0-11227}

![Forest plots demonstrating the sensitivity (left) and specificity (right) of urinary survivin mRNA expression. Squares indicate the estimates of sensitivity and specificity from each study; horizontal bars correspond to the 95% CIs; diamonds indicate the pooled sensitivity and specificity. CI, confidence interval; Q, Cochran χ^2^ test.](ol-19-02-1165-g02){#f3-ol-0-0-11227}

![Forest plots demonstrating the sensitivity (left) and specificity (right) of urine cytology. Squares indicate the estimates of sensitivity and specificity from each study; horizontal bars correspond to the 95% CIs; diamonds indicate the pooled sensitivity and specificity. CI, confidence interval; Q, Cochran χ^2^ test.](ol-19-02-1165-g03){#f4-ol-0-0-11227}

![SROC curves for (A) urinary survivin mRNA expression and (B) urine cytology. Circles represent each study. Demonstrated are SROC curves with confidence and prediction regions around the mean operating sensitivity and specificity point. SROC, summary receiver operating characteristic; SENS, sensitivity; SPEC, specificity; AUC, area under the curve.](ol-19-02-1165-g04){#f5-ol-0-0-11227}

![LR scattergrams for (A) urinary survivin mRNA expression and (B) urine cytology. A Fagan plot is included below each scattergram, demonstrating the relationship between the prior probability specified by the user (range, 0--1), the likelihood ratio (combination of sensitivity and specificity) and posterior test probability. LR, likelihood ratio.](ol-19-02-1165-g05){#f6-ol-0-0-11227}

![Deeks\' funnel plot asymmetry test was performed to identify publication bias. The results indicated poor likelihood for publication bias in the present meta-analysis. Each solid circle represents a study in the meta-analysis. ESS, effective sample size.](ol-19-02-1165-g06){#f7-ol-0-0-11227}

###### 

Characteristics of the studies included in the meta-analysis.

                                                                         Urinary survivin mRNA expression   Urine cytology                                  
  --------------------------- ---------- ------------------------------- ---------------------------------- ---------------- ---- ----- ---- --- ---- ----- -----------------------
  Weikert *et al*, 2005       Germany    Histopathology                  24                                 0                11   33    11   1   24   32    ([@b19-ol-0-0-11227])
  Pu *et al*, 2008            China      Histopathology                  104                                2                11   56    53   0   62   58    ([@b20-ol-0-0-11227])
  Pina-Cabral *et al*, 2007   Portugal   Histopathology                  20                                 0                10   20    9    0   21   20    ([@b31-ol-0-0-11227])
  Al-Maghrebi *et al*, 2012   Kuwait     Cystoscopy and histopathology   70                                 1                10   24    32   1   48   24    ([@b30-ol-0-0-11227])
  Eissa *et al*, 2013         Egypt      Cystoscopy and histopathology   35                                 2                11   38    23   0   23   40    ([@b21-ol-0-0-11227])
  Eissa *et al*, 2010         Egypt      Histopathology                  126                                12               40   200   80   0   86   212   ([@b32-ol-0-0-11227])
  Eissa *et al*, 2010         Egypt      Histopathology                  33                                 2                9    41    12   0   30   43    ([@b33-ol-0-0-11227])
  Jiang *et al*, 2006         China      Histopathology                  32                                 2                3    48    18   0   17   50    ([@b34-ol-0-0-11227])
  Lin *et al*, 2007           China      Histopathology                  45                                 1                3    29    14   0   34   30    ([@b35-ol-0-0-11227])
  Liu *et al*, 2009           China      Histopathology                  53                                 4                7    16    15   0   45   20    ([@b36-ol-0-0-11227])
  Pu *et al*, 2008            China      Histopathology                  60                                 1                4    19    26   0   38   20    ([@b37-ol-0-0-11227])
  Wan *et al*, 2008           China      Cystoscopy and histopathology   60                                 4                12   37    23   0   49   41    ([@b38-ol-0-0-11227])
  Wang *et al*, 2004          China      Histopathology                  38                                 0                2    15    27   0   13   15    ([@b39-ol-0-0-11227])
  Wang *et al*, 2006          China      Cystoscopy and histopathology   47                                 1                1    15    28   0   20   16    ([@b40-ol-0-0-11227])
  Zhang *et al*, 2005         China      Histopathology                  59                                 3                11   47    34   0   36   50    ([@b41-ol-0-0-11227])

TP, true positive; FP, false positive; FN, false negative; TN, true negative.

###### 

Comparisons of prime diagnostic indicators between the detection of urinary survivin mRNA expression and urine cytology.

  Parameter    Urine survivin mRNA (95% CI)   Urine cytology (95% CI)   P-value                      
  ------------ ------------------------------ ------------------------- --------- ------------------ --------
  Pooled Sen   0.86                           (0.81--0.90)              0.42      (0.36--0.48)       \<0.01
  Grade                                                                                              
    G1         0.79                           (0.73--0.85)              0.05      (0.01--0.12)       \<0.01
    G2         0.84                           (0.79--0.88)              0.35      (0.26--0.44)       \<0.01
    G3         0.84                           (0.76--0.90)              0.79      (0.66--0.88)       \>0.05
  Pooled Spe   0.95                           (0.93--0.96)              1.00      (0.98--1.00)       \>0.05
  γ            0.81                                                     0.42                         \<0.05
  PLR          16.40                          (11.60--23.20)            178.50    (25.10--1269.70)   --
  NLR          0.14                           (0.10--0.20)              0.59      (0.53--0.65)       --
  DOR          88.99                          (57.35--138.08)           40.39     (20.13--81.06)     --
  SAUC         0.95                           (0.93--0.97)              0.86      (0.83--0.89)       \>0.05

CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio; γ, Youden\'s index; DOR, diagnostic odds ratio; Spe, specificity; Sen, sensitivity; -, not available; SAUC, summary area under the curve.
